NuCana (NASDAQ:NCNA) Trading Down 2.7% – Here’s Why

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s share price traded down 2.7% on Monday . The company traded as low as $3.62 and last traded at $3.62. 35,344 shares changed hands during mid-day trading, a decline of 44% from the average session volume of 63,000 shares. The stock had previously closed at $3.72.

Analyst Ratings Changes

NCNA has been the topic of several recent analyst reports. Wall Street Zen raised NuCana from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, NuCana presently has a consensus rating of “Sell”.

NuCana Stock Down 2.7%

The stock has a market capitalization of $108,600.00, a PE ratio of -0.02 and a beta of 1.59. The firm has a 50 day moving average price of $4.23 and a 200-day moving average price of $7.46.

NuCana (NASDAQ:NCNA) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($2.69) by $2.59. Equities analysts expect that NuCana PLC Sponsored ADR will post -13.42 earnings per share for the current fiscal year.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.